학술논문

Recombinant herpes vector-mediated analgesia in a primate model of hyperalgesia
Document Type
Report
Source
Molecular Therapy. March, 2006, Vol. 13 Issue 3, p589, 9 p.
Subject
Gene therapy -- Models
Gene therapy -- Analysis
Analgesics -- Models
Analgesics -- Analysis
Immunohistochemistry -- Models
Immunohistochemistry -- Analysis
Peptides -- Models
Peptides -- Analysis
Gene expression -- Models
Gene expression -- Analysis
Universities and colleges -- Models
Universities and colleges -- Analysis
Monkeys -- Models
Monkeys -- Analysis
Herpes -- Models
Herpes -- Analysis
Herpesvirus diseases -- Models
Herpesvirus diseases -- Analysis
Neurosciences -- Models
Neurosciences -- Analysis
Pain -- Care and treatment
Pain -- Models
Pain -- Analysis
Language
English
ISSN
1525-0016
Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ymthe.2005.08.023 Byline: David C. Yeomans (1), Ying Lu (2), Charles E. Laurito (2), Michael C. Peters (1), Gina Vota-Vellis (2), Steven P. Wilson (3), George D. Pappas (4) Keywords: enkephalin; opiate; pain; gene expression; gene therapy; C fiber Abstract: Some chronic pain syndromes are characterized by episodes of intense burning and hyperalgesia in localized areas of skin. These sensations are thought to be mediated, at least in part, by the activity of damaged, unmyelinated C nociceptors. These phenomena were modeled by assaying responses of macaques to thermal and chemical stimuli that produced periodic activation and sensitization of C nociceptors. Upon validation of this method, a recombinant herpes simplex vector encoding human preproenkephalin was topically applied to the dorsal surface of the feet of the monkeys. Immunohistochemistry and radioimmunoassay revealed that enkephalin peptides were being produced in releasable pools in sensory neurons innervating the treated skin area. Behavioral responses evoked by periodic sensitization and activation of C nociceptors innervating the vector-treated skin area revealed a substantial and long-lasting (at least 20 weeks) antihyperalgesic and analgesic effect limited to the areas to which the virus was applied. This approach may be a viable means of treating localized cutaneous burning pain and hyperalgesia. Author Affiliation: (1) Department of Anesthesia and Stanford Pain and Analgesia Research Center, Stanford University School of Medicine, Stanford, CA 94305-5117, USA (2) Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL 60612, USA (3) Department of Pharmacology, Physiology and Neuroscience, University of South Carolina School of Medicine, Columbia, SC 20208, USA (4) Psychiatric Institute, University of Illinois at Chicago, Chicago, IL 60612, USA Article History: Received 6 October 2004; Revised 31 August 2005; Accepted 31 August 2005